The Spanish Pharma Sector Leads R&D Investment in 2020 and Reaches 18.5% of the Entire Industry

The pharmaceutical industry is getting stronger in the year of the COVID-19 pandemic. In 2020, this sector reached 18.5% of the total investment in Research and Development (R&D) of the Spanish industry. The turnover of pharmaceutical companies accounts for 2.2% in the total of the Spanish industry, but it is at the forefront in “R&D intensity,” according to Farmaindustria’s 2020 annual report.

One in four researchers in the Spanish industrial sector works in the pharmaceutical industry. In total, the pharmaceutical industry has 5,965 employees in the research area and is also a leader in terms of the prominent presence of women, with two-thirds of jobs being held by women.

The sector also became, in the Covid-19 year, one of the main drivers of the Spanish economy due to its export levels. In 2020, the pharmaceuticals industry recorded a record 12,777 million euros in foreign sales, representing a growth of 5.6% compared to 2019.

Read more about the Spanish pharma sector and find the most important business headlines from around the world with the Born2Invest mobile app.

The industry generates 42,643 direct jobs, of which 94% are permanent

Medicines are the country’s fourth most exported product and account for 4.9% of total Spanish exports and represent more than 22% of high-tech exports.

The industry generates 42,643 direct jobs, 94% of which are permanent, and also generates 170,000 indirect jobs. On the other hand, one out of every three new workers in the sector corresponds to young people, and more than half of them are women.

Pharmaceuticals was the industrial sector with the most patent applications in Spain in 2019, with 155 applications, followed by the health technology and transport sectors, with 126 and 118 applications respectively.

In 2020, 1,019 studies were approved, of which eight out of ten are promoted by the pharmaceutical industry

Regarding the role of clinical trials directly related to the pharmaceutical industry, there are currently more than 3,400 underway in Spain. A total of 145,000 patients participate in these trials. In 2020, 1,019 studies were approved, of which eight out of ten are promoted by the pharmaceutical industry.

Thirty-four percent of these correspond to drugs to treat different types of cancer, followed by trials of treatments against Covid-19, which account for 14%.

__

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.